CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $3 | $4 | $12 | $13 |
| Gross Profit | -$3 | -$4 | -$12 | -$13 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,290 | $14,096 | $9,300 | $9,805 |
| G&A Expenses | $0 | $4,770 | $0 | $0 |
| SG&A Expenses | $5,608 | $4,770 | $5,621 | $4,668 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$4 | $0 | $0 |
| Operating Expenses | $14,899 | $18,861 | $14,921 | $14,473 |
| Operating Income | -$14,902 | -$18,865 | -$14,933 | -$14,486 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $44 | $14 | -$341 | -$9 |
| Pre-Tax Income | -$14,858 | -$18,851 | -$15,274 | -$14,495 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14,858 | -$18,851 | -$15,274 | -$14,495 |
| % Margin | – | – | – | – |
| EPS | -38.87 | -60 | -134.64 | -6.36 |
| % Growth | 35.2% | 55.4% | -2,017% | – |
| EPS Diluted | -38.87 | -60 | -134.64 | -6.36 |
| Weighted Avg Shares Out | 317 | 6,225 | 2,261 | 1,411 |
| Weighted Avg Shares Out Dil | 317 | 6,225 | 2,261 | 1,458 |
| Supplemental Information | – | – | – | – |
| Interest Income | $60 | $28 | $0 | $0 |
| Interest Expense | $16 | $14 | $7 | $9 |
| Depreciation & Amortization | $3 | $4 | $12 | $13 |
| EBITDA | -$14,838 | -$18,861 | -$15,255 | -$14,473 |
| % Margin | – | – | – | – |